| |
| | Merrill Lynch - Markets & Research - /markets_news_story/0,2263,{AF4876E1-8733-4379-8EE0-8636DF599284},00.html (Site not responding. Last check: 2007-11-06) |
 | | MIAMI, Nov 24, 2004 (BUSINESS WIRE) -- IVAX Corporation IVX (LSE:IVX.L) confirmed that earlier this month, IVAX, in collaboration with its marketing and distribution partner, Combino Pharm SL, was first to market an injectable paclitaxel alternative to Bristol-Myers Squibb's anti cancer drug, Taxol(R) in Spain. |
 | | Combino Pharm SL is a leading generic company in Spain, dedicated to the hospital market. |
 | | Combino Pharm SL representatives will work closely with hospital pharmacists to ensure Paxene is included in oncology center protocols throughout Spain. |
| askmerrill.ml.com /markets_news_story/1,2263,{AF4876E1-8733-4379-8EE0-8636DF599284},00.html (352 words) |
|